Prelude Therapeutics Incorporated cash flow to debt ratio of -316.50% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Prelude Therapeutics Incorporated's free cash flow has increased -45.62% from $-103.65M last year to $-56.37M, signaling increasing performance

Prelude Therapeutics Incorporated's debt to equity ratio is 0.13, which means that the company's assets are healthy financed, signaling financial stability.

Prelude Therapeutics Incorporated's debt has decreased relative to shareholder equity from 0.14 last year to 0.13 today, signaling strengthened financials

Prelude Therapeutics Incorporated has a net cash position, so leverage is healthy.

Interest expense is not separately reported in Prelude Therapeutics Incorporated's latest filing, so interest coverage cannot be calculated.

Prelude Therapeutics Incorporated's profit margin has increased (-85.15%) in the last year from -1.82K% to -269.75%, signaling increasing performance

Prelude Therapeutics Incorporated's short-term assets of $105.69M exceed its short-term liabilities of $52.99M

Prelude Therapeutics Incorporated's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Prelude Therapeutics Incorporated's return on equity of -75.35%, is lower than 15.00%, indicating bad performance

Prelude Therapeutics Incorporated's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Prelude Therapeutics Incorporated had positive net income in only 0 out of 5 years, indicating unstable earnings

Prelude Therapeutics Incorporated has negative free cash flow, indicating the company is burning cash rather than generating it

Prelude Therapeutics Incorporated has negative free cash flow, indicating cash burn

Prelude Therapeutics Incorporated's yearly earnings has increased -21.76% since last year from $-127.17M to $-99.50M, signaling increasing performance

Prelude Therapeutics Incorporated's yearly revenue has increased 73.43% since last year from $7.00M to $12.14M, signaling increasing performance

ROIC -43.74% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Prelude Therapeutics Incorporated has insufficient revenue history to calculate 3-year revenue CAGR.

Prelude Therapeutics Incorporated had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Prelude Therapeutics Incorporated had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Prelude Therapeutics Incorporated has insufficient data to evaluate this check.

Prelude Therapeutics Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Prelude Therapeutics Incorporated is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Prelude Therapeutics Incorporated has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Prelude Therapeutics Incorporated has insufficient data to evaluate this check.

Prelude Therapeutics Incorporated has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Prelude Therapeutics Incorporated has a price-to-book ratio of 3.55x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Prelude Therapeutics Incorporated has a price-to-sales ratio of 21.19x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue